NeuroPace

NeuroPace runs a hardware-plus-recurring-services model: hospitals and surgical centers buy the implanted RNS System device for each patient, and NeuroPace also collects recurring revenue from follow-on services tied to the device's operation. The RNS System is a closed-loop neurostimulator that detects and responds to epileptic brain activity in real time. Surgeons implant it, and patients then visit clinicians who use NeuroPace's cloud-based software platform to review the device's recorded brain data and tune stimulation parameters over the life of the implant. That ongoing data review and programming access generates service-type revenue that recurs annually or per patient. The economics are structurally similar to other implantable medical-device businesses. The upfront hardware sale covers the device and disposables associated with the implant procedure. The margin profile improves over time as the installed base grows, because each new device adds another patient generating recurring service revenue without a proportional increase in the cost to support them. Clinical evidence and regulatory exclusivity (first and only FDA-approved closed-loop brain stimulator) create a durable moat, but the business requires significant upfront R&D and clinical-trial investment to earn each regulatory indication. No specific revenue or margin figures are available given the company's pre-revenue or private disclosure status.